Comparison between prolozone therapy and extracorporeal shockwave therapy in management of pain and function in resistant cases of lateral epicondylitis: a randomised controlled trial

Authors

  • Margaret Chabungbam Department of Physical Medicine and Rehabilitation, RIMS, Imphal, Manipur, India
  • Akoijam Joy Singh Department of Physical Medicine and Rehabilitation, RIMS, Imphal, Manipur, India
  • Longjam Nilachandra Singh Department of Physical Medicine and Rehabilitation, RIMS, Imphal, Manipur, India
  • Yumnam Ningthemba Department of Sports Medicine, RIMS, Imphal, Manipur, India
  • Sreejith C. Department of Physical Medicine and Rehabilitation, RIMS, Imphal, Manipur, India
  • Janet Moirangthem Department of Physical Medicine and Rehabilitation, RIMS, Imphal, Manipur, India
  • Chandrakant Pilania Department of Physical Medicine and Rehabilitation, RIMS, Imphal, Manipur, India
  • Tasso Opo Department of Physical Medicine and Rehabilitation, RIMS, Imphal, Manipur, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20203121

Keywords:

Extracorporeal shockwave therapy, Lateral epicondylitis, Prolozone

Abstract

Background: Lateral epicondylitis also known as the tennis elbow is a painful condition of the elbow caused by overuse. The disease imparts significant disability to those affected in terms of the quantity and quality of work done.

Methods: A randomised controlled trial was conducted in the Department of Physical Medicine and Rehabilitation, RIMS, Imphal for a period of 1 year from February 2017 to January 2018. Eighty-four patients with resistant lateral epicondylitis recruited were divided into 2 groups- group A received Prolozone injection while group B underwent Extracorporeal Shockwave Therapy (ESWT).

Results: Assessments of VAS (Visual Analog Scale) and PRTEE (Patient Rated Tennis Elbow Evaluation) were done at 8 weeks and 24 weeks. The mean VAS score in Prolozone group improved from 7.22±0.89 to 4.04±1.01 at 8 weeks to 1.67±0.70 at end of 24 weeks. In ESWT group, mean VAS score improved to 3.91±0.72 at 8 weeks and reduced to 2.3±0.68 at end of 24 weeks. PRTEE improved significantly in both the groups, from 85.33±3.29 to 24.87±2.10 in Prolozone group, and from 85.17±2.83 to 41.89±3.17 in ESWT group.

Conclusions: The improvement in pain and disability is better in prolozone group than ESWT (p<0.05) in chronic lateral epicondylitis.

References

Terry CS, Beaty JH. Shoulder and elbow injuries. In: Terry CS, editor. Campbell’s operative orthopaedics. 11th Edn. Missouri: Mosby; 2008:2634-2638.

Taylor SA, Hannafin JA. Evaluation and management of elbow tendinopathy. Sports Health. 2012;4(5):384-93.

Canale ST, James HB. Shoulder and elbow injuries. In: Canale ST,editor. Campbell’s Operative Orthopedics. 10th Edn. Missouri: Mosby; 2003:2361-2365.

Singh A, Gangwar DS, Singh S. Injection of bone marrow concentrates for treatment of refractory tennis elbow. Saudi J Sports Med. 2013;13(2):98-101.

Smidt N, van der Windt DA, Assendelft WJ, devillé WL, Korthals-de Bos IB, Bouter LM. Corticosteroid injections, physiotherapy or a wait-and-see policy for lateral epicondylitis: a randomised controlled trial. Lancet. 2002;359(9307):657-62.

Childress MA, Beutler A. Management of chronic tendon injuries. Am Fam Physician. 2013;87(4):486-90.

Scarpone M, Rabago DP, Zgierska A, Arbogast G, Snell E. The efficacy of prolotherapy for lateral epicondylosis: a pilot study. Clin J Sport Med. 2008;18(3):248-54.

Shin J, Seo KM, Kim DK, Kim BK, Kang SH. The effect of prolotherapy on lateral epicondylitis of elbow. J Korean Acad Rehabil Med. 2002;26(1):764-68.

Park JH, Song IS, Lee JB. Ultrasonographic findings of healing of torn tendon in patients with lateral epicondylitis after prolotherapy. J Korean Soc Med Ultrasound. 2003;22(3):177-83.

Downloads

Published

2020-07-21

Issue

Section

Original Research Articles